Published On: Wed, Sep 13th, 2017

Analysts Watch Trillium Therapeutics Inc. (TRIL) And Issue New Targets


Recently stock market analysts have updated their consensus ratings on shares of Trillium Therapeutics Inc. (TRIL).

Most recent broker ratings

07/17/2017 – H.C. Wainwright began new coverage on Trillium Therapeutics Inc. giving the company a “buy” rating. They now have a USD 7 price target on the stock.

06/08/2017 – Trillium Therapeutics Inc. had its “buy” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 18 price target on the stock.

11/03/2016 – Trillium Therapeutics Inc. had its “outperform” rating reiterated by analysts at Cowen.

11/02/2016 – Trillium Therapeutics Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 20 price target on the stock.

10/06/2016 – BTIG Research began new coverage on Trillium Therapeutics Inc. giving the company a “buy” rating. They now have a USD 21 price target on the stock.

06/06/2016 – Trillium Therapeutics Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 38 price target on the stock.

Trillium Therapeutics Inc. has a 50 day moving average of 4.58 and a 200 day moving average of 5.31. The stock’s market capitalization is 54.51M, it has a 52-week low of 4.15 and a 52-week high of 17.70.

The share price of the company (TRIL) was up +10.99%, with a high of 5.05during the day and the volume of Trillium Therapeutics Inc. shares traded was 245635.